Novartis AG ADR (NVS)vsTaseko Mines Ltd (TGB)
NVS
Novartis AG ADR
$150.75
+1.44%
HEALTHCARE · Cap: $286.27B
TGB
Taseko Mines Ltd
$6.20
+4.03%
BASIC MATERIALS · Cap: $2.26B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 8322% more annual revenue ($56.67B vs $672.90M). NVS leads profitability with a 24.7% profit margin vs -4.5%. TGB appears more attractively valued with a PEG of 0.33. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
TGB
Hold46
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-243.7%
Fair Value
$48.62
Current Price
$150.75
$102.13 premium
Intrinsic value data unavailable for TGB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 27.8%
Generating 1.6B in free cash flow
Growing faster than its price suggests
Revenue surging 45.3% year-over-year
Areas to Watch
2.2% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Earnings declined 11.6%
Elevated debt levels
Weak financial health signals
ROE of -4.7% — below average capital efficiency
Earnings declined 45.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 27.8%.
Bull Case : TGB
The strongest argument for TGB centers on PEG Ratio, Revenue Growth. Revenue growth of 45.3% demonstrates continued momentum. PEG of 0.33 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, PEG Ratio.
Bear Case : TGB
The primary concerns for TGB are Debt/Equity, Piotroski F-Score, Return on Equity. Debt-to-equity of 1.58 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVS profiles as a value stock while TGB is a hypergrowth play — different risk/reward profiles.
TGB carries more volatility with a beta of 1.89 — expect wider price swings.
TGB is growing revenue faster at 45.3% — sustainability is the question.
NVS generates stronger free cash flow (1.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 46/100), backed by strong 24.7% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Taseko Mines Ltd
BASIC MATERIALS · COPPER · USA
Taseko Mines Limited, a mining company, acquires, develops and operates mineral properties. The company is headquartered in Vancouver, Canada.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?